methimazole embryofetopathy
Methimazole embryopathy is a teratogenic embryofetopathy that results from maternal exposition to methimazole (MMI; or the parent compound carbimazole) in the first trimester of pregnancy. MMI is an antithyroid thionamide drug used for the treatment of Graves' disease. In the infant, MMI may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short upslanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia/hypothelia.
MONDO:0002254
syndromic disease
is_a
MONDO:0016677
toxic or drug-related embryofetopathy
is_a
MMI/CMZ embryofetopathy
exact
MMI/CMZ embryopathy
exact
Methimazole antenatal exposure
related
Methimazole/carbimazole embryofetopathy
exact
Methimazole/carbimazole embryopathy
exact
fetal methimazole syndrome
related
foetal methimazole syndrome
related
methimazole embryofetopathy
exact